Evolus, Inc. Common Stock · NASDAQ:EOLS
Evolus, Inc. Common Stock — Q3 2026 Earnings Presentation
39 slides from Evolus, Inc. Common Stock's earnings presentation, Nov 4, 2026
Slide 1: Evolus
@CVOLUS in 2volus
Slide 2: Investor Presentation November 2026
INVESTOR PRESENTATION November 2026 2
Slide 3: Disclosures: Forward Looking Statements
DISCLOSURES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future resul
Slide 4: Performance Beauty
PERFORMANCE QUALITY SAFETY INNOVATION EFFICACY BEAUTY ACCESSIBLE BEAUTY EXPERIENCE CREATIVE EXPRESSION 4
Slide 5: A Compelling Investment Opportunity
A COMPELLING INVESTMENT OPPORTUNITY JEUVEAU®: FLAGSHIP PRODUCT IS UNDERPENETRATED SCALED, BEAUTY FIRST TOXIN AESTHETICS MARKET Strengthening mid-teens market share in the Supports long-term growth U.S. and expanding internationally EVOLYSSE®: POSITIONED FOR Cash-pay business model with a MULTI-YEAR
Slide 6: Differentiated Portfolio Combines Beauty First Toxin with First New HA Technology
DIFFERENTIATED PORTFOLIO COMBINES A FAST-GROWING BEAUTY FIRST TOXIN WITH THE FIRST NEW HA TECHNOLOGY IN A DECADE Proven Performance with proven safety in 5 clinical First HA Made with Cold-X® Technology which uses studies and the largest Phase 3 study against near-freezing temperatures designed to p
Slide 7: A More Diversified and Scaling Portfolio
A MORE DIVERSIFIED AND SCALING PORTFOLIO U.S. Portfolio Expansion with Three Injectable Verticals Supported by a Pipeline That Will Deliver Three New Products Over The Next Four Years • A scaled neurotoxin foundation with Jeuveau® , which has achieved 14% market share across more than 19,000 account
Slide 8: Portfolio and approval timeline
Hair MID-FACE VOLUME FDA Approval in Q4 2026 (Expected) HAIR GROW TH & DENSITY Early Stage NASOLABIAL FOLDS Received FDA Approval; Launched in U.S. in Q2 2025 FDA Approval 2019 SKIN QUALITY NASOLABIAL FOLDS FDA Approval in 2030 (Expected) Received FDA Approval; Launched in U.S. in Q2 2025 VOLUMIZING
Slide 9: Growing Our Neurotoxin Presence in Large & Underpenetrated Markets
GROWING OUR NEUROTOXIN PRESENCE IN LARGE & UNDERPENETRATED MARKETS EVOLUS IS LAUNCHED IN THE MARKETS WITH THE JEUVEAU® SHARE OF U.S. NEUROTOXIN MARKET BIGGEST OPPORTUNITY OVER THE LAST FEW YEARS* 16% 14% 14% 12% 13% 10% 11% 8% 9% 6% 7% 7% 4% 4% 2% 0% 2019 2020 2021 2022 2023 2024 2025 U.S. Launched
Slide 10: Long Term Global Aesthetic Market Is a Growth Market
LONG TERM GLOBAL AESTHETIC MARKET IS A GROWTH MARKET UNDERLYING DEMAND FOR AESTHETIC PROCEDURES REMAINS RESILIENT WITH DERMAL FILLER MARKET EXPERIENCING CORRECTION FILLERS NEUROTOXINS $6.8B $5.9B $2.5B $3.9B $2.4B $2.0B $4.3B $3.5B $1.9B 2019 2025 2028 7% CAGR 5% CAGR Notes: Evolysse® is licensed in
Slide 11: Strong Historical Revenue Growth
STRONG HISTORICAL REVENUE GROWTH CONSISTENTLY OUTPACING THE MARKET WITH DOUBLE-DIGIT REVENUE GROWTH FOR SIX CONSECUTIVE YEARS ~40% CAGR $297.2M $266.3M $202.1M $148.6M $99.7M $56.5M 2020 2021 2022 2023 2024 2025 11
Slide 12: A Performance Beauty Platform
STRUCTURAL CUSTOMER ADVANTAGE PARTNERSHIP Cash-pay model Co-branded marketing, enables scale and education, and training profitability aligned to practice economics and commercial success LEADING DIGITAL CONSUMER ECOSYSTEM LOYALTY + Integrated digital platform FREQUENCY that simplifies operations, R
Slide 13: Differentiated Cash Pay Business Model
DIFFERENTIATED CASH PAY BUSINESS MODEL WHY CASH PAY? Supports value proposition by: • Eliminating third-party reimbursement complexity • Delivering flexible, customer-driven pricing • Enabling scalable co-branded marketing partnerships • Driving consumer demand directly to our customers • Building d
Slide 14: Co-Branded Marketing That Empowers Customers
CO-BRANDED MARKETING THAT EMPOWERS CUSTOMERS 400M+ IMPRESSIONS FROM 2025 CAMPAIGNS OUT-OF-HOME ADVERTISING PAID SOCIAL ADS STREAMING TV INFLUENCER CONTENT CREATION 14
Slide 15: Medical Education That Supports Customers
MEDICAL EDUCATION THAT SUPPORTS CUSTOMERS IN 2026: LIVE EVENTS EVOLUS ACADEMY MEDICAL AFFAIRS TEAM 500+ 4K+ 12K+ INJECTORS EDUCATED INJECTORS EDUCATED 2026 full-year projections as of October 2026. 15
Slide 16: Digital Capabilities Bridging Customer and Consumer Engagement
DIGITAL CAPABILITIES BRIDGING CUSTOMER AND CONSUMER ENGAGEMENT CONNECTS CUSTOMERS Simplifies AND CONSUMERS PURCHASING AND through digital engagement INVENTORY MANAGEMENT PROVIDES DASHBOARDS Activates co-branded media to & METRICS BUILD AWARENESS AND to measure what matters DRIVE DEMAND ENABLES PRICI
Slide 17: Modern Loyalty Program
MODERN LOYALTY PROGRAM Evolux® is Evolus’ portfolio-wide loyalty program that rewards customers for purchasing across Jeuveau® and Evolysse® with transparent pricing benefits and increased co-branded media support based on their total combined spend. 17
Slide 18: A Digitally Native, Growing Millennial Consumer Base
A DIGITALLY NATIVE, GROWING MILLENNIAL CONSUMER BASE DRIVING LONG TERM DEMAND • More likely to engage through mobile-first experiences • High quality expectations support premium, branded aesthetics • Self-care orientation drives repeat, preventative treatments • Social connectivity accelerates awar
Slide 19: Demand Shifting Toward Millennials and Gen Z
DEMAND SHIFTING TOWARD MILLENNIALS AND GEN Z PROJECTED TO REPRESENT >50% OF NORTH AMERICAN AESTHETIC SALES BY 2030 PROJECTED SHARE OF AESTHETICS PATIENTS BY GENERATION ADOPTION AMONG GEN Z & THE MILLENNIAL & 10% YOUNGER ≥1997 16% YOUNGER DEMOGRAPHIC: 35% MILLENNIAL 1981 – 1996 38% AT LEAST 3X AS LIK
Slide 20: Digital Loyalty Platform Driving Consumer Starts and Repeat Engagement
DIGITAL LOYALTY PLATFORM THAT DRIVES NEW CONSUMER STARTS AND REPEAT ENGAGEMENT INSTANT EASY CO-BRANDED t Text Message Today 9:41 AM Nice work! Your specialist should now be providing you with a $40 discount on your treatment today. 20
Slide 21: Rewards Engagement Is Scaling with Repeat Usage
REWARDS ENGAGEMENT IS SCALING WITH REPEAT USAGE DRIVING INCREASED CONSUMER LOYALTY EVOLUS REWARDS ENROLLMENTS SURPASSED EXISTING PATIENTS DRIVE A GROWING SHARE OF 1.6 MILLION IN Q3 20261 REWARDS REDEMPTIONS REINFORCING LOYALTY1 >1.6M 5000 TOTAL CONSUMER REDEMPTIONS (000s) 70% >1.5M EXISTING CONSUMER
Slide 22: Market Expansion Opportunity—Fillers
MARKET EXPANSION OPPORTUNITY—FILLERS TOXINS AND FILLERS ARE THE TOP 2 MEDICAL AESTHETIC PROCEDURES FILLERS ARE THE #2 SERVICE PROVIDED FILLERS ARE THE #1 ADD-ON PROCEDURE ACROSS ALL CHANNELS FOR TOXIN USERS 1 2 FILLER 48% PLASTIC TOXINS FILLERS SURGEONS: SKINCARE 18% SKIN DERMATOLOGISTS: TOXINS FILL
Slide 23: Evolysse: An Innovative Technology That Complements the Jeuveau Brand
EVOLYSSE AN INNOVATIVE TECHNOLOGY ® THAT COMPLEMENTS THE JEUVEAU BRAND ® 23
Slide 24: Symatese Science Genesis
SYMATESE SCIENCE GENESIS 25+ YEARS IN R&D AND MANUFACTURING OF AESTHETICS & MEDICAL BIOMATERIALS LAUNCHED FIRST PEROUSE PLASTIE LAUNCH OF 2 PRODUCTS: BREAST IMPLANTS NEVELIA®, DERMAL HEMOTESE® & SOLD TO MENTOR REGENERATION COLLAPAT®II MATRIX 1997 2003 2004 2007 2011 2013 2021 SOLD RIGHTS OF XpresHAn
Slide 25: First HA Injectable Innovation Breakthrough in a Decade
FIRST HA INJECTABLE INNOVATION BREAKTHROUGH IN A DECADE HYLACROSS® OBT® COLD-X® TECHNOLOGY TECHNOLOGY TECHNOLOGY 1996 2000 2005 2008 2015 2025 NASHA® VYCROSS® PNT® TECHNOLOGY TECHNOLOGY TECHNOLOGY Based on the first regulatory approval date for each technology 25
Slide 26: Evolysse Manufacturing
EVOLYSSE® MANUFACTURING COLD-X® TECHNOLOGY BY SYMATESE CROSS-LINKING HA CONDITIONS • Typical cross-linking: Heat • Cold-X® cross-linking: Cold DESIGNED TO CREATE A MORE NATURAL INJECTABLE HA GEL • Cross-linking technology o Preserve the hyaluronic acid chain o Decrease fragmentation o Less BDDE is r
Slide 27: Evolysse Versatility
EVOLYSSE® VERSATILITY INDICATIONS • INDICATIONS RECEIVED FDA APPROVAL LAUNCHED IN U.S. Q2 2025 2026 | Q4 APPROVAL (EXPECTED) 2027 | APPROVAL (EXPECTED) 27
Slide 28: Profhilo: The Gold Standard That Defines Skin Quality in Europe
PROFHILO® THE GOLD STANDARD THAT DEFINES SKIN QUALITY IN EUROPE A CATEGORY-LEADING BRAND EXPANDS EVOLUS INTO A DISTINCT THIRD INJECTABLE VERTICAL 70+ 4.8M+ 2015 81% 86% COUNTRIES TREATMENTS GLOBAL OF HCPS SATISFIED/ OF PATIENTS SATISFIED/ WORLDWIDE LAUNCH VERY SATISFIED VERY SATISFIED CATEGORY-DEFIN
Slide 29: GLP-1 Adoption: A Durable Tailwind for Aesthetics
GLP-1 ADOPTION: A DURABLE TAILWIND FOR AESTHETICS WEIGHT LOSS ADOPTION IS EXPANDING THE PATIENT FUNNEL AND CREATING NEW, VISIBLE NEEDS ACROSS FACIAL VOLUME, SKIN LAXITY, AND SKIN QUALITY 1 in 7 70% $2.0B U.S. adults had taken a GLP-1 of providers plan to increase projected 2030 market for drug by Ju
Slide 30: Evolus Is Uniquely Positioned for the GLP-1 Opportunity
EVOLUS IS UNIQUELY POSITIONED FOR THE GLP-1 OPPORTUNITY A COMPLEMENTARY INJECTABLE PORTFOLIO CAN ADDRESS THE PRINCIPAL FACIAL EFFECTS OF WEIGHT LOSS ACROSS EXPRESSION, STRUCTURE, AND SKIN QUALITY TOXIN FILLER SKIN Jeuveau® treats dynamic lines, an Evolysse® restores facial volume Profhilo® adds a fu
Slide 31: Financials
lov 2volus FINANCIALS
Slide 32: Q3 2026 Results
Q3 2026 RESULTS Q3 NET REVENUE DELIVERED FOURTH CONSECUTIVE QUARTER OF PROFITABILITY1 AND REAFFIRMED FY 2026 $78.0M REVENUE OUTLOOK $69.0M $78.0M NET REVENUE, UP 13% Y-O-Y • Continued momentum of Jeuveau® $61.1M • Continued ramp of Evolysse® • Continued expansion of the international portfolio • Com
Slide 33: Accelerating Operating Leverage
DOUBLE-DIGIT TOTAL REVENUE GROWTH NET REVENUE WITH A LARGELY FLAT COST BASE DRIVES ACCELERATING OPERATING +11% – +13% LEVERAGE IN 2026: 11% – 13% PROJECTED DOUBLE DIGIT REVENUE GROWTH $330M – $337M MINIMAL NON-GAAP $297.2M 0% – 2% OPERATING EXPENSE1 GROWTH $202.1M $266.3M $148.6M LOW – ADJUSTED EBIT
Slide 34: Expanding Operating Leverage
EXPANDING OPERATING LEVERAGE • Consistent operating leverage delivered through 2024 • 2025 reflected a planned investment year with the addition of Evolysse®, marking the evolution to a multi-product portfolio • Beginning in 2026, with the portfolio foundation in place, Evolus is positioned to deliv
Slide 35: FY 2026 Outlook
FY 2026 OUTLOOK UPDATED GUIDANCE AND EXPECTATIONS: • Reaffirms full-year 2026 total net revenues of $330 million to $337 million, which represents 11% to 13% growth over the prior year. 1 • Reaffirms full-year 2026 adjusted gross profit margin of 67.0% to 67.5%. • Updates non-GAAP operating expenses
Slide 36: Long-Term Outlook
lov 2volus LONG-TERM OUTLOOK
Slide 37: 2028 Long-Term Outlook
REFLECTING: • A durable, differentiated portfolio, anchored by the long-term growth trajectory of Jeuveau®, increasing contribution from the Evolysse® collection, and a 2028 LONG-TERM pipeline runway that continues to build on the performance beauty strategy OUTLOOK PROJECTING • Growing market share
Slide 38: Thank You
@VOLUS THANK YOU
Slide 39: Non-GAAP Information
NON-GAAP INFORMATION Within this presentation, “profitability” is defined as achieving positive Adjusted EBITDA. Adjusted gross profit excludes amortization of an intangible asset from gross profit. Adjusted gross profit margin is adjusted gross profit as a percentage of total net revenues. Historic